Proteomic changes upon treatment with semaglutide in individuals with obesity
Authors' conclusion
This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities.
Study context
- Population
- Participants with overweight or obesity, with or without diabetes, in STEP 1 and STEP 2STEP 1 n = 1,311
- Comparison
- Semaglutide
- Outcome
- Circulating proteome
- Follow-up
- End of treatment
Methodological detailsbaseline and end-of-treatment serum samples
- Baseline and end-of-treatment serum samples
Main finding
As reported in the abstract
- Broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways
- Several proteins regulated with semaglutide after accounting for changes in body weight and HbA1c at end of trial, suggesting effects beyond weight loss and glucose lowering
- Comparison with real-world proteomic profiles: potential benefits on disease-specific signatures, incl. downregulation of specific proteins associated with CVD risk
Original publication
Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat Med. Published 3 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →